Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 28, 2021; 27(16): 1738-1750
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1738
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1738
Figure 2 Clinical features and hepatological changes due to severe acute respiratory syndrome coronavirus 2 infection (upper panel) and hepatotoxic effects of some drugs used as an attempt to treat coronavirus disease 2019 (lower panel).
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; AST: Aspartate aminotransferase.
- Citation: Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750
- URL: https://www.wjgnet.com/1007-9327/full/v27/i16/1738.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i16.1738